# The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis

> **NCT00536120** · PHASE4 · COMPLETED · sponsor: **Biogen** · enrollment: 60 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** BG00002 (natalizumab)
- **BIOLOGICAL:** keyhole limpet hemocyanin (KLH)
- **BIOLOGICAL:** tetanus diphtheria toxoid vaccine (Td)

## Key facts

- **NCT ID:** NCT00536120
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2009-11
- **Final completion:** 2009-12
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2017-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00536120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00536120, "The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00536120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*